Nageshwar Budha

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess et al. · The Lancet Oncology · 2018 · 658 citations · Full text

Medicine, Dermatology, Oncology +14

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

John A. Flygare, Maureen H. Beresini, Nageshwar Budha et al. · Journal of Medicinal Chemistry · 2012 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development

Gillian S. Smelick, Timothy P. Heffron, Laura Chu et al. · Molecular Pharmaceutics · 2013 · 188 citations

Medicine, Oncology, Pharmacology +14

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

Cristina Saura, Desamparados Roda, Susana Roselló et al. · Cancer Discovery · 2016 · 171 citations · Full text

Medicine, Oncology, Pharmacology +14

A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents

Julian G. Hurdle, Robin B. Lee, Nageshwar Budha et al. · Journal of Antimicrobial Chemotherapy · 2008 · 107 citations · Full text

Life Sciences, Microbiology, Pharmacology +17